Study
| Open-label, randomized, phase 2 trial (NCT04661150) |
| Resectable, HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma Atezolizumab + trastuzumab + XELOX (arm A) vs. trastuzumab + XELOX (arm B), perioperative regimen (3 neoadjuvant + 5 adjuvant cycles) |
Efficacy
| pCR: 38.1% vs. 14.3% (arm A vs. B) (difference: 23.8% [90% CI: 1.3–44.7]) |
| MPR: 42.9% vs. 19.0% |
| R0 resection rate: 95.2% vs. 90.5% |
| Median EFS, DFS, and OS: Not reached in either group (follow-up: 15.7 months) |
| |
Safety
| Grade ≥3 TEAEs: 57% vs. 67% |
| AE-related discontinuation: 24% vs. 19% |
| Most common grade ≥3 AEs: weight decrease (10% vs. 19%), neutrophil count decrease (5% vs. 14%) |
| |
JAMA Oncol 2025; published online April 17
http://doi.org/10.1001/jamaoncol.2025.0522
Reviewed by Ulas D. Bayraktar, MD on May 4, 2025
